Cambridge Healthtech Institute’s 28th Annual
Recombinant Protein Production - Part 2
January 20-21, 2027
As therapeutic protein production continues to expand beyond traditional antibodies, teams are under growing pressure to deliver novel proteins faster, more effectively, and at greater scale—because no matter how much protein is produced, demand only continues to grow. Cambridge Healthtech Institute’s 28th Annual Recombinant Protein Production – Part 2 conference focuses on complex recombinant therapeutic proteins and the strategies needed to move them from design to usable material more efficiently. This year’s program examines challenging therapeutic formats including bispecifics, trispecifics, tetraspecifics, T cell engagers, bispecific ADCs, VHH-, Fab-, scFv-, and fusion-based multispecifics, as well as cytokines, growth factors, receptor ligands, miniproteins, therapeutic peptides, AAVs, and other difficult biologics. The agenda explores approaches for predicting expressibility early and producing toxic, unstable, disulfide-rich, or host-stressing proteins. The conference closes with the ever-popular protein workflows session, focused on production through the lens of AI-enabled decision-making, in-house versus outsourced strategies, and managing multiple high-priority projects with speed, quality, and risk in mind. Join colleagues to share case studies, platform strategies, and practical solutions for producing increasingly complex biologics faster and more reliably.
Coverage will include, but is not limited to:
PRODUCING MULTISPECIFIC PROTEINS AND THEIR COMPONENTS
- Bispecific, trispecific, and tetraspecific formats
- Bispecific ADCs
- T cell engagers
- scFV-Fab, VHH, and fusion-based multispecifics
- Predicting expressibility early
- Cell-free for early bispecific and multispecific format screening before committing to a cell line
PRODUCTION BEYOND ANTIBODIES: CYTOKINES, MINI PROTEINS, AND DIFFICULT BIOLOGICS
- Disulfide-rich therapeutic proteins
- Toxic, unstable, or host-stressing therapeutic proteins
- AAVs
- Cytokines, growth factors, receptor ligands, and other non-antibody biologics.
- Mini proteins
- Therapeutic peptide production
DISCOVERY-SCALE PRODUCTION WORKFLOWS
- AI in production workflows
- In-source vs. outsource decisions
- Managing multiple high-priority projects
- Closing panel: What can we make, how fast, and with what risk?
The deadline for priority consideration is June 26, 2026.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: